|
1
|
Ben M'na A, Chelly I, Souissi A, Azzouz H,
Haouet S, Mokni M, Kchir N and Ben Osman A: Primary cutaneous
osteosarcoma. Ann Dermatol Venereol. 140:206–208. 2013.(In French).
PubMed/NCBI
|
|
2
|
Osborne TS and Khanna C: A review of the
association between osteosarcoma metastasis and protein
translation. J Comp Pathol. 146:132–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meyers PA: Muramyl tripeptide
(mifamurtide) for the treatment of osteosarcoma. Expert Rev
Anticancer Ther. 9:1035–1049. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taran SJ, Taran R and Malipatil NB:
Pediatric osteosarcoma: An updated review. Indian J Med Paediatr
Oncol. 38:33–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harrison DJ, Geller DS, Gill JD, Lewis VO
and Gorlick R: Current and future therapeutic approaches for
osteosarcoma. Expert Rev Anticancer Ther. 18:39–50. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hattinger CM, Fanelli M, Tavanti E, Vella
S, Ferrari S, Picci P and Serra M: Advances in emerging drugs for
osteosarcoma. Expert Opin Emerg Drugs. 20:495–514. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li S, Sun W, Wang H, Zuo D, Hua Y and Cai
Z: Research progress on the multidrug resistance mechanisms of
osteosarcoma chemotherapy and reversal. Tumour Biol. 36:1329–1338.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dumoutier L, Louahed J and Renauld JC:
Cloning and characterization of IL-10-related T cell-derived
inducible factor (IL-TIF), a novel cytokine structurally related to
IL-10 and inducible by IL-9. J Immunol. 164:1814–1819. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zindl CL, Lai JF, Lee YK, Maynard CL,
Harbour SN, Ouyang W, Chaplin DD and Weaver CT: IL-22-producing
neutrophils contribute to antimicrobial defense and restitution of
colonic epithelial integrity during colitis. Proc Natl Acad Sci
USA. 110:12768–12773. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li P, Shi X, Xu Y, Zhong B, Lu Y and Sun
Y: Interleukin-22 promotes osteosarcoma cell proliferation and
invasion via STAT3 activation. Med Sci Monit. 24:7802–7808. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Q and Wang K: The induction of
ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the
sensitivity of osteosarcoma cells to cisplatin. Cell Biol Int.
43:1245–1256. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen C, Zhao M, Tian A, Zhang X, Yao Z and
Ma X: Aberrant activation of Wnt/β-catenin signaling drives
proliferation of bone sarcoma cells. Oncotarget. 6:17570–17583.
2015.PubMed/NCBI
|
|
14
|
Li QC, Xu H, Wang X, Wang T and Wu J:
miR-34a increases cisplatin sensitivity of osteosarcoma cells in
vitro through up-regulation of c-Myc and Bim signal. Cancer
Biomark. 21:135–144. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Waidmann O, Kronenberger B, Scheiermann P,
Köberle V, Mühl H and Piiper A: Interleukin-22 serum levels are a
negative prognostic indicator in patients with hepatocellular
carcinoma. Hepatology. 59:12072014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rui J, Chunming Z, Binbin G, Na S, Shengxi
W and Wei S: IL-22 promotes the progression of breast cancer
through regulating HOXB-AS5. Oncotarget. 8:103601–103612. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Xu J, Chen J, Jin S, Yao J, Yu T,
Wang W and Guo R: IL-22 confers EGFR-TKI resistance in NSCLC via
the AKT and ERK signaling pathways. Front Oncol. 9:11672019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rudloff I, Jarde T, Bachmann M, Elgass KD,
Kerr G, Engel R, Richards E, Oliva K, Wilkins S, McMurrick PJ, et
al: Molecular signature of interleukin-22 in colon carcinoma cells
and organoid models. Transl Res. Oct 31–2019.PubMed/NCBI
|
|
19
|
Graziano AC, Cardile V, Avola R, Vicario
N, Parenti C, Salvatorelli L, Magro G and Parenti R: Wilms' tumor
gene 1 silencing inhibits proliferation of human osteosarcoma MG-63
cell line by cell cycle arrest and apoptosis activation.
Oncotarget. 8:13917–13931. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Perry JA, Kiezun A, Tonzi P, Van Allen EM,
Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS,
et al: Complementary genomic approaches highlight the PI3K/mTOR
pathway as a common vulnerability in osteosarcoma. Proc Natl Acad
Sci USA. 111:E5564–E5573. 2016. View Article : Google Scholar
|
|
21
|
Tang H and Xue G: Major physiological
signaling pathways in the regulation of cell proliferation and
survival. Handb Exp Pharmacol. 249:13–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lou L, Zhou J, Liu Y, Wei YI, Zhao J, Deng
J, Dong B, Zhu L, Wu A, Yang Y and Chai L: Chlorogenic acid induces
apoptosis to inhibit inflammatory proliferation of IL-6-induced
fibroblast-like synoviocytes through modulating the activation of
JAK/STAT and NF-κB signaling pathways. Exp Ther Med. 11:2054–2060.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li HX, Zhao W, Shi Y, Li YN, Zhang LS,
Zhang HQ and Wang D: Retinoic acid amide inhibits JAK/STAT pathway
in lung cancer which leads to apoptosis. Tumour Biol. 36:8671–8678.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Donegan JJ, Patton MS, Chavera TS, Berg
KA, Morilak DA and Girotti M: Interleukin-6 attenuates serotonin 2A
receptor signaling by activating the JAK-STAT pathway. Mol
Pharmacol. 87:492–500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu Z, Lu X, Jiang L, Sun X, Zhou H, Jia
Z, Zhang X and Ma L: STAT3 signaling pathway is involved in
decitabine induced biological phenotype regulation of acute myeloid
leukemia cells. Am J Transl Res. 7:1896–1907. 2015.PubMed/NCBI
|
|
26
|
Kim BH, Yi EH and Ye SK: Signal transducer
and activator of transcription 3 as a therapeutic target for cancer
and the tumor microenvironment. Arch Pharm Res. 39:1085–1099. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Villarino AV, Kanno Y, Ferdinand JR and
O'Shea JJ: Mechanisms of Jak/STAT signaling in immunity and
disease. J Immunol. 194:21–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bi Y, Cao J, Jin S, Lv L, Qi L, Liu F,
Geng J and Yu Y: Interleukin-22 promotes lung cancer cell
proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT
signaling pathways. Mol Cell Biochem. 415:1–11. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu J, Xiao Z, Zhao R, Lu C and Zhang Y:
Paeoniflorin suppressed IL-22 via p38 MAPK pathway and exerts
anti-psoriatic effect. Life Sci. 180:17–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Basu R, O'Quinn DB, Silberger DJ, Schoeb
TR, Fouser L, Ouyang W, Hatton RD and Weaver CT: Th22 cells are an
important source of IL-22 for host protection against
enteropathogenic bacteria. Immunity. 37:1061–1075. 2012. View Article : Google Scholar : PubMed/NCBI
|
